Skip to content

Walking improves the cognitive function of schizophrenic subjects

Improvement of Cognitive functions in sedentaRy schizophrEnic subjects following 1-year of guided Walking (CREW): a pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN14763786
Enrollment
40
Registered
2021-01-26
Start date
2017-11-13
Completion date
Unknown
Last updated
2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia Mental and Behavioural Disorders Schizophrenia

Interventions

Forty sedentary patients diagnosed with schizophrenia are allocated to a 1-year Guided Walking program (GW n=28), consisting of two walking sessions per week, or to a Cognitive Rehabilitation program

Sponsors

University of Ferrara
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients diagnosed with schizophrenia since at least 1 year 2. On antipsychotic medications with the same therapeutic regimen for at least 3 months before enrolment 3. Free of symptomatic peripheral arterial occlusive disease and cardiovascular, pulmonary, neurological, metabolic, and orthopaedic disorders that could interfere with the walking activity

Exclusion criteria

Exclusion criteria: 1. Recent modification of therapeutic regimen 2. Presence of symptomatic peripheral arterial occlusive disease and cardiovascular, pulmonary, neurological, metabolic, and orthopaedic disorders that could interfere with the walking activity

Design outcomes

Primary

MeasureTime frame
1. Feasibility was evaluated through the number of dropouts between baseline the end of the study 2. Adherence was measured by the number of walking sessions attended by the participants during the one year program (using patient records) 2. Cognitive function assessed with the Screen for Cognitive Impairment in Psychiatry (SCIP) and the Frontal Assessment Battery (FAB) at baseline and after one year.

Secondary

MeasureTime frame
Cardiovascular risk factors were evaluated only in the subjects that followed the walking program (at baseline and after 1-year, at the end of the walking program): 1. Blood pressure (mmHg, sphygmomanometer) 2. Anthropometric variables - height (m), weight (kg), BMI (kg/m² and waist circumference (cm) 3. VO2peak was indirectly determined using the 1-kilometer walking test (1k-WT). Five minutes of slow walking preceded the test. Subjects were instructed to select a pace that they could maintain for 10 to 20 min at a moderate perceived exercise intensity, (11–13 on the 6–20 Borg scale). Heart rate was monitored continuously using a Polar Accurex Plus heart rate monitor (Polar Electro, Kempele, Finland). The equation for VO2 peak determination considering age, BMI, HR and time to complete the 1 k-TWT was then applied

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 18, 2026